TR4 anticorps (pSer192)

N° du produit ABIN802023

Détail du produit anti-TR4 anticorps

Antigène: TR4 (NR2C2) (Nuclear Receptor Subfamily 2, Group C, Member 2 (NR2C2))

Épitope: pSer192

Reactivité: Humain, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TR4 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))

Réactivité croisée: Humain, Rat

Homologie: Mouse,Cow,Pig,Horse,Chicken,Rabbit

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic phosphopeptide derived from human TAK1 around the phosphorylation site of Ser192

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Références pour anticorps anti-TR4 (ABIN802023)

Su, Zhou, Wang, Yang, Li, Yu, Li: "The PPARβ/δ agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFκB pathway in rats." dans: Inflammation, Vol. 37, Issue 3, pp. 729-37, (2014) (PubMed).

Détails sur TR4

Antigène: TR4 (NR2C2) (Nuclear Receptor Subfamily 2, Group C, Member 2 (NR2C2))

Autre désignation: TAK1 (NR2C2 Produits)

Synonymes: anticorps TAK1, anticorps TR2R1, anticorps TR4, anticorps hTAK1, anticorps Tr4, anticorps gb:dq017625, anticorps im:6911408, anticorps mKIAA4145, anticorps nuclear receptor subfamily 2 group C member 2, anticorps nuclear receptor subfamily 2, group C, member 2, anticorps NR2C2, anticorps Nr2c2, anticorps nr2c2

Sujet:

Synonyms: MAP3K7phospho S192, M3K7_HUMAN, MAP3K 7, Map3k7, MEKK7, Mitogen activated protein kinase kinase kinase 7, Mitogen-activated protein kinase kinase kinase 7, Mitogen-activated protein kinase kinase kinase 7, TAK1, TGF beta activated kinase 1, TGF-beta-activated kinase 1, TGF1a, Transforming growth factor beta activated kinase 1, Transforming growth factor-beta-activated kinase 1.

Background: TAK1 (or MAP3K7) was shown to participate in regulation of transcription by transforming growth factor beta (TGF beta). TAK1 is stimulated in response to TGF beta and bone morphogenetic protein. These results suggest that TAK1 functions as a mediator in the signaling pathway of TGF beta superfamily members. TAB1 and TAB2 are TAK1 binding proteins that may function as activators of the TAK1 (TGF b activated kinase 1) MAPKKK in TGF b signal transduction. TAB1 induced TAK1 activation promoted the dissociation of active forms of IKKa and IKK b from active TAK1, whereas the IKK mutants remained to interact with active TAK1. TNF a activated endogenous TAK1, and the kinase negative TAK1 acted as a dominant negative inhibitor against TNF a induced NFkB activation. TAK1 was suggested to act as a regulatory kinase of IKKs.

ID gène: 7182

Pathways: TCR Signaling, Nuclear Receptor Transcription Pathway, Steroid Hormone Mediated Signaling Pathway, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Tube Formation, Toll-Like Receptors Cascades